Neurobiology Research Unit, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
Nucl Med Biol. 2010 Jan;37(1):35-40. doi: 10.1016/j.nucmedbio.2009.08.005. Epub 2009 Oct 3.
Several dopamine D(2) agonist radioligands have been used with positron emission tomography (PET), including [(11)C-]-(-)-MNPA, [(11)C-]-(-)-NPA and [(11)C]-(+)-PHNO. These radioligands are considered particularly powerful for detection of endogenous dopamine release, but they either provide PET brain images with limited contrast or have affinity for both D(2) and D(3) receptors. We here present the carbon-11 radiolabeling and ex vivo evaluation of 2-Cl-(-)-NPA, a novel PET-tracer candidate with high in vitro D(2)/D(3) selectivity.
2-Cl-[(11)C]-(-)-NPA and [(11)C]-(-)-NPA were synthesized by a two step N-acylation-reduction process using [(11)C]-propionyl chloride. Awake rats were injected with either tracer, via the tail vein. The rats were decapitated at various times, the brains were removed and quickly dissected, and plasma metabolites were measured. Radioligand specificity, and P-glycoprotein involvement in brain uptake, was also assessed.
2-Cl-[(11)C]-(-)-NPA and [(11)C]-(-)-NPA were produced in high specific activity and purity. 2-Cl-[(11)C]-(-)-NPA accumulated slower in the striatum than [(11)C]-(-)-NPA, reaching maximum concentrations after 30 min. The maximal striatal uptake of 2-Cl-[(11)C]-(-)-NPA (standard uptake value 0.72+/-0.24) was approximately half that of [(11)C]-(-)-NPA (standard uptake value 1.37+/-0.18). Nonspecific uptake was similar for the two compounds. 2-Cl-[(11)C]-(-)-NPA was metabolized quickly, leaving only 17% of the parent compound in the plasma after 30 min. The specific binding of 2-Cl-[(11)C]-(-)-NPA was completely blocked and inhibition of P-glycoprotein did not alter the brain uptake.
Ex vivo experiments showed, despite a favorable D(2)/D(3) selectivity, that 2-Cl-[(11)C]-(-)-NPA is inferior to [(11)C]-(-)-NPA as a PET tracer in rat, because of slower brain uptake and lower specific to nonspecific binding ratio.
几种多巴胺 D2 激动剂放射性配体已被用于正电子发射断层扫描 (PET),包括 [(11)C]-(-)-MNPA、[(11)C]-(-)-NPA 和 [(11)C]-(+)-PHNO。这些放射性配体被认为特别适合检测内源性多巴胺释放,但它们要么提供对比度有限的 PET 脑图像,要么对 D2 和 D3 受体都有亲和力。我们在此介绍了新型 PET 示踪剂候选物 2-Cl-(-)-NPA 的碳-11 放射性标记和体外评价,该化合物具有高体外 D2/D3 选择性。
使用 [(11)C]-丙酰氯通过两步 N-酰化-还原过程合成 2-Cl-[(11)C]-(-)-NPA 和 [(11)C]-(-)-NPA。通过尾静脉向清醒大鼠注射示踪剂。在不同时间点将大鼠断头,取出大脑并快速解剖,测量血浆代谢物。还评估了放射性配体的特异性和 P-糖蛋白在脑摄取中的参与情况。
2-Cl-[(11)C]-(-)-NPA 和 [(11)C]-(-)-NPA 以高比活度和纯度合成。2-Cl-[(11)C]-(-)-NPA 在纹状体中的积累速度比 [(11)C]-(-)-NPA 慢,30 分钟后达到最大浓度。2-Cl-[(11)C]-(-)-NPA 的最大纹状体摄取量(标准摄取值 0.72±0.24)约为 [(11)C]-(-)-NPA 的一半(标准摄取值 1.37±0.18)。两种化合物的非特异性摄取相似。2-Cl-[(11)C]-(-)-NPA 代谢迅速,30 分钟后血浆中仅残留 17%的母体化合物。2-Cl-[(11)C]-(-)-NPA 的特异性结合完全被阻断,而 P-糖蛋白的抑制并没有改变脑摄取。
尽管体外实验显示 2-Cl-[(11)C]-(-)-NPA 具有有利的 D2/D3 选择性,但与 [(11)C]-(-)-NPA 相比,作为大鼠的 PET 示踪剂,它的脑摄取速度较慢,特异性与非特异性结合的比值较低。